Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) EBITDA (2016 - 2025)

Historic EBITDA for iBio (IBIO) over the last 17 years, with Q4 2025 value amounting to -$9.0 million.

  • iBio's EBITDA fell 10549.95% to -$9.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$24.8 million, marking a year-over-year decrease of 6103.46%. This contributed to the annual value of -$18.6 million for FY2025, which is 1183.12% down from last year.
  • Per iBio's latest filing, its EBITDA stood at -$9.0 million for Q4 2025, which was down 10549.95% from -$5.7 million recorded in Q3 2025.
  • In the past 5 years, iBio's EBITDA ranged from a high of -$3.4 million in Q2 2024 and a low of -$10.6 million during Q4 2022
  • Over the past 5 years, iBio's median EBITDA value was -$5.5 million (recorded in 2021), while the average stood at -$6.3 million.
  • As far as peak fluctuations go, iBio's EBITDA tumbled by 22226.02% in 2021, and later soared by 5747.66% in 2023.
  • Over the past 5 years, iBio's EBITDA (Quarter) stood at -$7.2 million in 2021, then crashed by 46.22% to -$10.6 million in 2022, then surged by 57.48% to -$4.5 million in 2023, then grew by 2.94% to -$4.4 million in 2024, then crashed by 105.5% to -$9.0 million in 2025.
  • Its EBITDA was -$9.0 million in Q4 2025, compared to -$5.7 million in Q3 2025 and -$5.2 million in Q2 2025.